4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. (FDMT) priced its initial public offering on Dec 14, 2020 at $23.00 per share, within its $22.00–$23.00 range, raising $193.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $580.4M. Goldman Sachs was lead-left underwriter, joined by BofA Securities and Evercore ISI. Latham & Watkins advised the company and Cooley advised the underwriters.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that develops product candidates using targeted and evolved AAV vectors. Its Therapeutic Vector Evolution platform applies directed evolution to about one billion synthetic capsid sequences, aiming to treat diseases ranging from rare to common.

Status

IPO

Ticker

FDMT

Exchange

Nasdaq Global Select

Priced

Dec 14, 2020

IPO price

$23.00

Price range

$22.00–$23.00

Raised

$193.2M

Market cap at IPO price

$580.4M

First filed

Sep 30, 2019

Underwriters

Goldman Sachs, BofA Securities and Evercore ISI

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.